News

TIXiMED Initiates Phase 1b Multiple Ascending Dose Study of TIX100

TIXiMED Appoints Stephen Daly and Albert R. Collinson, Ph.D., to Board of Directors

TIXiMED Announces Expansion of Program-Related Investment from the Helmsley Charitable Trust

TIXiMED Announces Promising Preclinical Data: Oral TIX100 Prevents Weight Regain After GLP-1 Cessation in Obesity Model

TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy

TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, its Investigational Disease-Modifying Treatment for Type 1 Diabetes

TIXiMED Announces a $2.65M Program-Related Investment from the Helmsley Charitable Trust to Initiate Clinical Trials of Its Novel Oral Therapy, TIX100, for Beta Cell Survival and Function

A recent publication in the journal Diabetes spotlights TIX100, an NCE in clinical stage development at TIXiMED as the first disease-modifying oral therapy for T1D, as more potent, specific, and effective than verapamil in inhibiting TXNIP, a detrimental protein in diabetes and a proven new target to protect beta cell health and islet cell function.  

As part of the celebration on the 75th anniversary of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a new article by TIXiMED Founder and CSO, Dr. Anath Shalev, entitled “Target Discovery to Diabetes Therapy – TXNIP from Bench to Bedside with NIDDK” has been published in the journal Endocrinology.

In it, Dr. Shalev chronicles how the support of NIDDK has contributed significantly to the identification of TXNIP as a new target in T1D (and beyond) as well as the discovery and development of a promising new oral beta cell treatment candidate in TIX100.

TIXiMED Chief Scientific Officer Presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) 

It was standing room only for a presentation at ATTD 2025 by TIXiMED Founder and CSO, Dr. Anath Shalev, on TIXNIP as an important treatment target in type 1 diabetes as well as TIXiMED’s progress in the development of TIX100.

We are pleased to announce that TIX100, our investigational oral therapy for T1D, was successfully dosed, and well tolerated, in the first cohort of healthy subjects in this first-in-human Single Ascending Dose study.

A new article in the journal Diabetes, Obesity and Metabolism entitled “Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity” and authored by TIXiMED founder and CSO, Dr. Anath Shalev and her team finds that TIX100, a novel, oral therapy for T1D and T2D, protects against weight gain while preserving lean mass and promotes islet beta cell survival (an underlying issue of T1D and T2D).

TIXiMED Chief Scientific Officer to Give a Presentation at the Advanced Technologies & Treatments for Diabetes (ATTD) Meeting

If you are attending the March Advanced Technologies & Treatments for Diabetes (ATTD) meeting in Amsterdam, please join us for a presentation by TIXiMED founder and CSO, Dr. Anath Shalev, in a session entitled “Beta Cell Therapies for Type 1 Diabetes” on March 20, beginning at 1PM CET in Hall B.

Find more information and the full ATTD 2025 scientific program here.

TIXiMED Receives IND Approval from the FDA for its Novel Oral Antidiabetic, TIX100

TIXiMED’s TIX100 is featured in a peer-reviewed article in Frontiers in Endocrinology as part of the Research Topic Disease-modifying approaches in type 1 diabetes.

NIH Funds Grant to Study TIX100 in MASLD/MASH

Podcast: DiabeticsDoingThings (DDT) Sat Down with TIXiMED Chief Scientific Officer to Discuss TIX100 

JDRF Invites TIXiMED Chief Scientific Officer to Speak at Global Type 1 Diabetes Cures Strategy Workshop

JDRF invited Anath Shalev, M.D., the Chief Scientific Officer of TIXiMED, Inc. and the Director of the UAB Comprehensive Diabetes Center, to the Global T1D Cures Strategy Workshop: Genetic Engineering Approaches for T1D Workshop in October of 2023. Shalev gave a talk in a session on Islet Targeting and Beta Cell Regeneration/Survival. She also discussed her work on targeting TXNIP for type 1 diabetes and drug development progress with the oral drug candidate TIX100.

TIXiMED Chief Scientific Officer Interviewed on Taking the Pulse: A Health Care Podcast

Anath Shalev, M.D., the Chief Scientific Officer of TIXiMED, Inc., recently appeared as a guest on Taking the Pulse: A Health Care Podcast.  On the podcast, Dr. Shalev, who serves as the Chief Clinical Officer and Director of the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB), discusses recent advancements in type 1 diabetes research as well as cutting-edge treatments and novel drug therapies.

Anath Shalev, M.D., TIXiMED’s Chief Scientific Officer, attended the Human Islet Research Network (HIRN) 2023 Annual Investigator Meeting in September. There, she chaired the session Beta Cells on Target: Small Molecules and Extracellular Vesicles in Type 1 Diabetes. Since 2019, Shalev has served as the chair of the HIRN Consortium on Beta Cell Death and Survival (CBDS).

TIXiMED Chief Scientific Officer Authors Study Published in Diabetes

In a study published in Diabetes, Anath Shalev, M.D. and Guanlan Xu, Ph.D. examine the mechanism underlying verapamil’s beneficial effect on type 1 diabetes. According to Dr. Shalev, the study’s results “reveal IGF-1 signaling as yet another previously unappreciated pathway affected by verapamil and TXNIP that may contribute to the beneficial verapamil effects in the context of Type 1 diabetes.” Dr. Shalev is the Chief Scientific Officer of TIXiMED, Inc., a company developing and commercializing TXNIP inhibiting medications as therapeutics for type 1 and type 2 diabetes.

TIXiMED Chief Scientific Officer Presents at 2023 Immunology of Diabetes Society Congress

Renowned diabetes researcher and Chief Scientific Officer of TIXiMED Dr. Anath Shalev presented her work on verapamil and TXNIP inhibition at the 2023 Immunology of Diabetes Society Congress in Paris.